Catching DDMAC's Eye: Leaving Out Risk Information Proves Risky Practice For ISTA
This article was originally published in The Pink Sheet Daily
Executive Summary
ISTA receives a second warning letter from FDA in just over a year for promotional material that omits risk information for its lead ophthalmic product.
You may also be interested in...
Safety Concerns Over Larger Bottle For ISTA's Bromday Could Impact Other Eye Drugs
FDA's Center for Drug Evaluation and Research refused to approve ISTA's sNDA for a larger fill size of the topical non-steroidal anti-inflammatory because it does not believe a single bottle should be used to dose drug in both eyes.
Safety Concerns Over Larger Bottle For ISTA's Bromday Could Impact Other Eye Drugs
FDA's Center for Drug Evaluation and Research refused to approve ISTA's sNDA for a larger fill size of the topical non-steroidal anti-inflammatory because it does not believe a single bottle should be used to dose drug in both eyes.
Vitrase Journal Ad Lacks Risk Information, FDA Says
The violative ad for the spreading agent omits warnings, the Division of Drug Marketing, Advertising & Communications states.